Home » Newsletters » BioWorld Science

BioWorld Science

Aug. 1, 2006

View Archived Issues

Gilead Sciences reviews operational and clinical progress

Rh-Apo2L completes phase I testing in China

CAT acquires oncology product candidate from Enzon

European phase III trial of Miraxion for Huntington's disease completes enrollment

New cancer drug discovery alliance for discovery of B-RAF inhibitors

Additional site for phase I/IIa multiple myeloma trial of atiprimod

Enzon and Santaris to codevelop and commercialize RNA antagonists

Zydus Cadila cleared for phase I studies of ZYH-2 for diabetes

Pharmacological efficacy of OST-4077 against accelerated bone loss

European orphan drug designation for CT-1

PharmaMar seeks European approval for Yondelis in soft tissue sarcomas

Prialt marketed in U.K. and Germany for severe chronic pain

Phase IIb study planned for elocalcitol in overactive bladder

Phase III results show utility of XELOX for metastatic colorectal cancer

Liposomal all-trans retinoic acid can cure acute promyelocytic leukemia

Wex continues TTX development, to terminate Esteve collaboration

BLP25 vaccine improves PSA levels in men with cancer recurrence after prostatectomy

p38MAPK inhibition with FR-167653 attenuates immediate dysfunction of transplanted islets in rats

Human anti-CD40 4D11 MAb as induction/maintenance therapy for kidney transplantation in monkeys

NF-kappaB inhibition with DHMEQ, attenuates development of cardiac allograft vasculopathy in mice

Teva launches Azilect for Parkinson's disease in US

Import approval for Busulfex in Japan

FDA approval for Humira in ankylosing spondylitis

MK-0431A for type 2 diabetes accepted for review

Recent patents reveal novel compounds with possible activity in metabolic disorders

New anticancer agents covered in recent patent literature

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for April 17, 2026.
MMP inhibitors divulged in Accure Therapeutics patent
BioWorld Science
Accure Therapeutics has reported new oligopeptide derivatives acting as matrix metalloproteinase-2 (MMP-2) and MMP-9 inhibitors. As such, they are described as...
News in brief
BioWorld Asia
BioWorld Asia briefs for April 14, 2026
Selective CBL-B inhibitor with improved safety profile disclosed
BioWorld Science
CBL-B is a RING-type E3 ubiquitin ligase that acts as a negative regulator of T-cell activation, contributing to immune homeostasis by limiting excessive immune...
MSD discloses new HCN1/2 blockers
BioWorld Science
Merck Sharp & Dohme LLC (MSD) has synthesized new indazole derivatives acting as potassium/sodium hyperpolarization-activated cyclic nucleotide-gated channel 1...